1 g follow-up (median, 6.6 years), 10 patients
died of a cardiac cause, 11 patients underwent transplan
2 One patient in the risperidone group
died of a cause regarded as unrelated to treatment.
3 or every individual in the United States who
died of a firearm injury in 2017, three survived, living
4 nt erectile dysfunction, and a third patient
died of a haemopericardium after receiving two bevacizum
5 The high MELD-Na group
died of a liver related cause in 1142/1632 (70%) as comp
6 The high MELD-Na group
died of a liver-related cause in 1142 out of 1632 (70%)
7 The 215 case patients who
died of a prescription opioid overdose in 2012 or 2013 w
8 (MDBK) cells from lung tissue of alpaca that
died of a severe respiratory infection.
9 A third sibling also
died of a similar presentation, but DNA was unavailable
10 One (2%) patient
died of a stent-related cause.
11 ients (two each in the 6- and 20-mg cohorts)
died of a treatment-emergent adverse event.
12 Data on all patients who had
died of AAA during the same time period were obtained fr
13 ne left ventricular ejection fraction</=35%)
died of acute heart failure unrelated to ventricular arr
14 One patient with mucinous cardiopathy
died of acute heart failure.
15 t received serum later in the disease course
died of acute infection.
16 normalities, including one family member who
died of acute leukemia.
17 In the myocarditis group, 17% (4 of 23)
died of acute rejection after transplantation.
18 tients in the cetuximab and pemetrexed group
died of adverse events compared with five (2%) of 289 tr
19 p and 25 in the docetaxel plus placebo group
died of adverse events possibly unrelated to disease pro
20 s more pronounced for children whose mothers
died of AIDS or tuberculosis compared to other causes of
21 with HIV, and more than 700 000 persons have
died of AIDS since the first cases were reported in 1981
22 with HIV, and more than 700 000 persons have
died of AIDS since the first cases were reported in 1981
23 09 women, of whom 165 died of ALS; women who
died of ALS were older (median age, 66 years; interquart
24 The WHI enrolled 161 809 women, of whom 165
died of ALS; women who died of ALS were older (median ag
25 CSF P-tau levels, compared with patients who
died of Alzheimer disease (AD) and other dementias.
26 The patient
died of an intracerebral hemorrhage 6 months after the a
27 k among recipients of organs from donors who
died of anoxic drug overdose and recipients of organs fr
28 t recipients received grafts from donors who
died of anoxic drug overdose.
29 11.4 y of follow-up, 3504 men and 3032 women
died of any cause in this cohort.
30 members of U.S. military service members who
died of any cause since September 11, 2001 (N=1,732).
31 There were 50,990 individuals who
died of any cause, and 3804 who emigrated and were lost
32 During follow-up, 3883 patients
died of any cause, and of these, 2131 deaths were the re
33 For individuals who
died of any cause, mean YLL was 31.4 years (95% CI 30.5-
34 Two animals
died of apparent infection, and all kits were resorbed i
35 factors and viral pathogens among those who
died of ARI at home.
36 ,947 person-years, 238 of 1226 (19.4%) women
died of ASVD-related causes.
37 conditional deletion of Dnmt1 in their Tregs
died of autoimmunity by 3 to 4 weeks of age unless they
38 We report an infant who
died of autoinflammation due to a homozygous missense mu
39 ich the T2/Onc transposon had been mobilized
died of B-ALL by 3 months of age.
40 ical ventilation for severe COVID-19 disease
died of bacterial pneumonia.
41 A total of 517 patients
died of breast cancer following a DCIS diagnosis (mean f
42 Cohabitees of patients who
died of cancer were less likely to die of any cause (IRR
43 Two patients
died of cancer within the first month.
44 ho died of cerebrovascular accident, 217 who
died of cancer, and 200 cardiovascular disease deaths.
45 of cardiovascular diseases, 433 individuals
died of cancer, and 55 individuals died of respiratory d
46 After she
died of cancer, her physician sister discovered, from th
47 Totally, 67 patients
died of cancer.
48 s and fathers 1 to 5 years after their child
died of cancer.
49 ical care services in adults whose cohabitee
died of cancer.
50 Of these, 58%
died of cardiac and 42% of noncardiac causes.
51 ring treatment, including one individual who
died of cardiac arrest that was possibly treatment-relat
52 Two thousand sixteen survivors
died of cardiac disease.
53 also had a duplication of chromosome 6p and
died of cardiac failure.
54 n the control group, all animals secondarily
died of cardiac/respiratory failure (8 of 10) or neurolo
55 Two patients
died of cardiogenic shock after the dissection.
56 follow-up period of 5.2 years, 203 patients
died of cardiovascular causes or were hospitalized for h
57 ical follow-up was available for 32 women; 5
died of cardiovascular complications within 1 year of di
58 participants died; of those, 350 individuals
died of cardiovascular diseases, 433 individuals died of
59 rly participant in the monotherapy group who
died of cardiovascular failure 13 days after randomisati
60 fewer comorbid conditions than did those who
died of causes other than SCD.
61 from a subject injected 10 years earlier who
died of causes unrelated to gene transfer.
62 l) in 15 (83%) of 18 individuals (2 patients
died of causes unrelated to medullary thyroid carcinoma)
63 lant before vCJD onset, from a donor who had
died of causes unrelated to vCJD.
64 No patients
died of CDI after a mean follow-up time of 1.8 years; ho
65 low-up, 793 subjects died, including 279 who
died of cerebrovascular accident, 217 who died of cancer
66 ning histories of women aged 55-79 years who
died of cervical cancer during 1980-2010 (cases) to thos
67 However, one patient
died of chronic rejection 1 year after having been switc
68 Her sister and a first cousin
died of cirrhosis (ages 19 and 6 years) and another 32-y
69 Patients who
died of CJD had elevated CSF T-tau levels and T-tau to P
70 ho were available for follow-up (one patient
died of CNS aspergillosis 29 d after RLT and another of
71 heal disease or comorbidity and subsequently
died of colitis.
72 fter a median of 10.9 years, 71 participants
died of colorectal cancer in the screening group vs 330
73 ectional study of all US service members who
died of combat or unintentional injuries in support of O
74 One recipient
died of complications of sepsis 4 months after achieving
75 ained in second complete remission, two (3%)
died of complications, and 19 (27%) relapsed.
76 ained in second complete remission, 13 (14%)
died of complications, and 21 (23%) relapsed after stem-
77 g-term complete remission rate of 93.8%; 111
died of concomitant disease and 2 of Barrett's esophagus
78 was 5.8% in these patients, but the majority
died of coronary artery disease (38%) and other causes (
79 first-ever nonfatal myocardial infarction or
died of coronary heart disease during follow-up (median
80 2020, more than 170 000 U.S. residents have
died of coronavirus disease 2019 (COVID-19); however, th
81 performed an autopsy on a single patient who
died of COVID-19 after open repair of an aortic dissecti
82 -CoV-2) globally, and more than 850,000 have
died of COVID-19.
83 the postmortem kidneys from 42 patients who
died of COVID-19.
84 ern California systems (55-90 years old) who
died of CRC from 2006 through 2012 and had >=5 years of
85 ith high rates of screening, most people who
died of CRC had failures in the screening process that c
86 mal results occurred in 8.1% of patients who
died of CRC vs 2.2% of cancer-free patients.
87 tervals, occurred in a 67.8% of patients who
died of CRC vs 53.2% of cancer-free patients; failure to
88 %) developed nodal metastases; and 21 (2.1%)
died of CSCC.
89 768 person-years of follow-up, 12,492 people
died of CVD.
90 5.3-7.6 y), 801 patients died; 342 of those
died of CVD.
91 Three patients with CSI nonseminoma
died of disease (0.3%).
92 patients demonstrated systemic metastases or
died of disease during a mean follow-up period of 10 mon
93 Eight patients
died of disease, all after R2 resection.
94 hese 18 patients (28% [18% of all patients])
died of disease-specific causes.
95 sis (range, 8.9-13.7 months), and 2 patients
died of disease.
96 tients are in clinical remission and only 8%
died of disease.
97 Four patients
died of disseminated disease and 52 patients were alive
98 patients from 7 ocular oncology centers who
died of dissemination were analyzed.
99 One patient in cohort A
died of drug-related complications of immune-related col
100 000 person-years [PY]) and 9 patients (0.2%)
died of EAC (0.7/1000 PY) in a mean 2.7 +/- 1.6 years.
101 mor recurrence, and the remaining 5 patients
died of early infections.
102 ymocyte globulin plus GVHD prophylaxis group
died of Epstein-Barr virus hepatitis, but no deaths were
103 Cases were defined as individuals who had
died of esophageal cancer, and controls were residents f
104 m the same area (three per case) who had not
died of esophageal cancer, matched by gender and birth y
105 of this cause, nearly 4-fold the number that
died of esophageal cancer.
106 l animals infected with EBOV-C05 or EBOV-C07
died of EVD, whereas 2 of 3 EBOV-K-infected animals died
107 ith and 4100 patients (76%) without diabetes
died of events of cardiovascular origin.
108 One 23-year-old patient in the placebo group
died of fat embolism, and another patient in the placebo
109 Among 7,529,481 cancer patients, 80,513
died of fatal stroke (with 262,461 person-years at risk)
110 We report a child who
died of FVH upon infection with hepatitis A virus (HAV)
111 Four percent of patients with AF
died of HCM-related causes (n=11), with annual mortality
112 significantly greater than that of those who
died of heart disease ($175 136), cancer ($173 383), or
113 849 of the 7,529,481 cancer patients studied
died of heart disease.
114 One patient
died of hemorrhage recurrence.
115 f the patients, respectively, and 2 patients
died of hepatic decompensation.
116 cessfully salvaged from those who ultimately
died of HL.
117 ped HS a median of 7 days post-transplant; 2
died of HS.
118 participants had a myocardial infarction or
died of IHD.
119 Two children
died of illnesses other than malaria and were RDT and BS
120 Three patients
died of infection 12 to 14 months after rituximab infusi
121 on (IFN) receptor (IFNAR) became viremic and
died of infection after a high-dose vaginal ZIKV challen
122 ificantly less patients with the GG genotype
died of infections (P=0.029).
123 e age 5 years in 2013, 51.8% (3.257 million)
died of infectious causes and 44% (2.761 million) died i
124 We aimed to describe children who
died of IPD since PCV introduction in England and Wales.
125 e of the patients experienced metastases nor
died of iris melanoma.
126 One patient on placebo
died of ischaemic heart disease.
127 Equal numbers in each group
died of ischemic heart disease.
128 al: 2,200, 5,807) life-years among those who
died of ischemic heart disease.
129 252 required dialysis or transplantation or
died of kidney disease, 335 developed end-stage kidney d
130 rom a dromedary camel and from a patient who
died of laboratory-confirmed MERS-CoV infection after cl
131 ty mice that received PD-treated splenocytes
died of lethal GVHD.
132 as postmortem brain tissue from a child that
died of leucine intoxication.
133 hs from unknown causes and a heart recipient
died of leukemia at 10 months.
134 h HCV monoinfection were more likely to have
died of liver cancer (odds ratio [OR] = 9.2), drug-relat
135 oinfected decedents were more likely to have
died of liver cancer (OR = 2.2) and drug-related causes
136 he human immunodeficiency virus (HIV) rarely
died of liver disease.
137 Two individuals
died of liver failure, and one individual was successful
138 Overall, 15 patients
died of liver-related complications and 26 developed hep
139 follow-up period of 6.99 years, 1,282 people
died of lower respiratory infection.
140 or one patient with pure (de novo) DLBCL who
died of lung cancer.
141 r patients with fee-for service Medicare who
died of lung or colorectal cancer, earlier hospice enrol
142 , or IFN-gamma receptor-deficient recipients
died of lymphoma, indicating that host IFN-gamma signali
143 We compared 10 patients who
died of malignant melanoma 3.7 years (median, range 0.9-
144 estimate, using model I, that 342,203 women
died of maternal causes in 2008, but that contraceptive
145 tly differentially expressed in patients who
died of MCL in both cohorts.
146 Of the 6 patients, 3
died of melanoma metastases and 1 of unrelated causes; 2
147 One patient
died of meningitis.
148 In August 2013, a 4-year-old boy
died of meningoencephalitis of unknown etiology in a Lou
149 One patient
died of metachronous cancer after STC.
150 follow-up of 120 months, 5% of patients had
died of metastases or secondary neoplasms, 81% were aliv
151 By the time of analysis, 37 patients had
died of metastasis after a median of 7 months.
152 well, 1 was alive with metastases, and 6 had
died of metastatic disease (including 2 patients who dec
153 with T3a (eyelid TNM)/T2 (Merkel TNM) tumors
died of metastatic MCC.
154 e diagnosed with metastasis and 12 out of 20
died of metastatic spread.
155 Approximately half of the patients
died of metastatic uveal melanoma (10-year rate, 48.5%;
156 r were obtained at autopsy from patients who
died of metastatic uveal melanoma to the liver.
157 However, 11
died of MLD progression, resulting in similar overall su
158 tients (94%), a patient with liver cirrhosis
died of multiorgan failure secondary to sodium overload.
159 e patient who had a combination of syndromes
died of multiorgan failure.
160 mesenteric ischemia, and the patient rapidly
died of multiple organ failure.
161 Furthermore, patients who
died of myeloma (n = 9) had a significantly higher MTV (
162 ease and in infarction areas of patients who
died of myocardial infarctions of different durations.
163 ce failed to control T. gondii infection and
died of necrotizing TE before day 77.
164 the human mitochondrial disease patient who
died of neonatal hypertrophic cardiomyopathy.
165 al weekly dosing scheme; 2 of these patients
died of neutropenic sepsis complications.
166 One elderly patient
died of neutropenic sepsis in the first brentuximab-AVD
167 2-1.51), none were shocked by the ICD, and 2
died of nonarrhythmic causes.
168 homozygous familial hypercholesterolemia but
died of noncardiac complications.
169 he PI arm and 14 in the pPCI arm, of whom 20
died of noncardiac reasons (13 in the PI and 7 in the pP
170 eas those with unintentional injury commonly
died of noninjury causes.
171 Forty-five pneumonectomy patients (18%)
died of nononcologic causes 1-5 years after surgery; pne
172 No Triplex recipient
died of nonrelapse causes during the first 100 days or h
173 One patient
died of nonrelapse mortality; 1 patient relapsed.
174 Of 1490 deceased patients, 620 (41.6%)
died of ocular melanoma.
175 with a necropsy analysis of worms that have
died of old age.
176 ve with confirmed metastases (n = 9) or have
died of other causes (n = 4).
177 ears), 7633 died of prostate cancer and 5575
died of other causes during a median follow-up of 4.9 ye
178 Some 952 men
died of other causes during surveillance, mainly cardiov
179 t subsequent ileal pouch-anal anastomosis, 2
died of other causes, and 3 were lost to follow-up.
180 1.49-2.09) for children who had a parent who
died of other causes.
181 s (median [range] age, 61 [29-71] years) who
died of other causes.
182 han patients with undiagnosed HAE-C1-INH who
died of other causes.
183 ose and recipients of organs from donors who
died of other causes.
184 ical ventricular reconstruction had SCD; 311
died of other causes.
185 t follow-up (2 to 36 months), three patients
died of other infectious complications, and one patient
186 nd 347 (0.34%) in the no screening group had
died of ovarian cancer.
187 and immunoglobulins, the patient ultimately
died of overwhelming sepsis.
188 espite immunomodulating therapy, the patient
died of overwhelming sepsis.
189 through 2014, a total of 8,354 participants
died of pancreatic cancer.
190 g follow-up through 2014, 8,354 participants
died of pancreatic cancer.
191 d those with a first-degree relative who had
died of PCa (FHD).
192 ctomy, those with first-degree relatives who
died of PCa did not have an increased likelihood of high
193 to vaccinated mothers required intubation or
died of pertussis.
194 positive patient with multiple sclerosis who
died of PML after receiving 45 infusions of natalizumab.
195 croscopy of brain biopsies from patients who
died of pneumococcal meningitis, we observe that pneumoc
196 One patient
died of pneumonia 24 weeks after implantation, which was
197 One patient
died of pneumonia and bacterial sepsis 1 year after ther
198 ity of Vo', a small town near Padua (Italy),
died of pneumonia due to severe acute respiratory syndro
199 Three patients
died of pneumonitis while in the study.
200 One patient who received triplet therapy
died of pneumonitis.
201 Two patients
died of pre-existing viral infections without having thy
202 One patient with baseline psoriasis
died of presumed immune-related colitis after a 1-week d
203 Only 2 patients, both in the NAFLD group,
died of primary liver cancer.
204 (interquartile range, 16.5-74.5); 2 patients
died of progressive CNS disease and small-cell lung canc
205 During BEP, 15 patients
died of progressive disease or toxicity, including one p
206 were alive and disease-free, eight (16%) had
died of progressive disease, and one patient (2%) each h
207 One patient
died of progressive multifocal leukoencephalopathy.
208 Results Among 31,790 patients, 7,365
died of prostate cancer and 11,811 died from other cause
209 29 136 patients (median age, 70 years), 7633
died of prostate cancer and 5575 died of other causes du
210 developed metastatic disease, and 1.5% have
died of prostate cancer.
211 erize the lethal cell clone in a patient who
died of prostate cancer.
212 In the preceding generation, the mother
died of pulmonary emphysema and she was blind after the
213 ectively, and two-thirds of MDS/AML patients
died of pulmonary fibrosis and/or hepatopulmonary syndro
214 We describe a patient who
died of rabies despite a neuroprotective intervention.
215 related mortality, and 2 additional children
died of rapid MLD progression 1.5 and 8.6 years after HS
216 d at relapse, and all patients in this group
died of rapidly progressive disease postrelapse.
217 p of 6.3 years, 4 of the 12 patients (33.3%)
died of recurrent EOC after a diagnosis of breast cancer
218 The remaining 5 recipients
died of recurrent hemorrhage (n=2), liver failure (n=1),
219 Four patients (5%)
died of refractory HIV+MCD and 80 achieved clinical remi
220 Only 1 patient
died of relapsed MCD (at fifth relapse 9.4 years after i
221 Twelve percent
died of related causes and 10% presented superinfection
222 apillary epithelial cell proliferations, and
died of renal failure by 3 mo of age.
223 cifically in kidney tubular epithelial cells
died of renal failure within weeks of birth.
224 dividuals died of cancer, and 55 individuals
died of respiratory diseases.
225 were HIV-uninfected; eight untested infants
died of respiratory infection (three), sepsis (two), bur
226 Despite therapeutic optimisation, she
died of respiratory insufficiency.
227 dy included 70 lung lobes of 14 patients who
died of reverse-transcription polymerase chain reaction-
228 all patients with PAH and 75.7% of those who
died of right heart failure received parenteral prostano
229 ly 0.18% of the kidney transplant population
died of SARS-CoV-2 infection.
230 One child and 3 adults
died of SCD and 2 adults were resuscitated from ventricu
231 Two patients in group B
died of sepsis after febrile neutropenia.
232 nsecutive cases was limited to 1 patient who
died of sepsis between 30 and 90 days.
233 enocytes taken post mortem from patients who
died of sepsis is profoundly suppressed, possibly becaus
234 up, one developed of Graves disease, and one
died of sepsis).
235 91 receiving treatment including doxorubicin
died of sepsis, three (1%) of 292 receiving treatment ex
236 One patient in the immunosuppression group
died of sepsis.
237 The patient had leukemia and neutropenia and
died of septic shock from KPC-producing E. gergoviae bac
238 Persons who rapidly
died of severe COVID-19 illness may not have had SARS-Co
239 a-cells as mice aged, and >50% of these mice
died of severe diabetic symptoms before reaching 1 year
240 esistant to systemic steroids, and 1 patient
died of severe interstitial lung disease.
241 Four children from two unrelated kindreds
died of severe pulmonary disease during infancy followin
242 t no LACDeltahla-infected rabbits (P < .005)
died of severe sepsis with disseminated infection.
243 follow-up without complications and 1 animal
died of shock after the subxiphoid puncture.
244 MNs alone suffered from severe illnesses or
died of similar viral challenges.
245 Extracts from brains of two patients, who
died of sporadic Creutzfeldt-Jakob disease (sCJD), conta
246 roke or cardiovascular disease, 532 patients
died of stroke (cases), and 57,734 remained free of inci
247 One patient with high baseline risk
died of stroke 7 years after implant.
248 he 1.6 million patients >70 years of age who
died of stroke since 2002, donor livers were retrieved f
249 There was 1 sepsis-related death, 1 patient
died of sudden hemoptysis, and 2 patients developed recu
250 resonance imaging in people who subsequently
died of sudden unexpected death in epilepsy.
251 (0.14%) and 1342 nonbereaved persons (0.07%)
died of suicide (IRR = 2.02 [95% CI, 1.75-2.34]); IRR =
252 2.61-4.52) for children who had a parent who
died of suicide, and IRR = 1.76 (95% CI, 1.49-2.09) for
253 In the surgery group, one (4%) patient
died of surgical complications and 12 (44%) patients had
254 One patient in the ECX group
died of suspected treatment-related neutropenic sepsis.
255 all patients with widespread chorioretinitis
died of systemic complications of M. chimaera infection
256 amily history was remarkable for an aunt who
died of systemic lupus erythematosus and for a brother w
257 atients, 9 (21%) were alive and 34 (79%) had
died of systemic metastasis.
258 (AGO2), and HEN1 RNA methyltransferase genes
died of TCV infection, whereas the wild-type Col-0 plant
259 on, similar to that observed in patients who
died of the 1918 H1N1 pandemic.
260 y, similar to that observed in patients that
died of the 1918 H1N1 pandemic.
261 Patient 2, whose sister and mother had
died of the disease, proceeded to transplantation at age
262 italization of an elderly male relative, who
died of the disease.
263 Twenty
died of the hemorrhage or associated illnesses, and we o
264 Two
died of the progression of preexisting heart failure wit
265 163 people as of 10 January 2014; 50 of them
died of the severe respiratory infection caused by these
266 All patients
died of their cancer within 6 months after the onset of
267 Four patients (1.6%)
died of their disease during follow-up.
268 Most patients with PAH in our cohort
died of their disease; however, right ventricular failur
269 5.6 per 1000 patients); 168 patients with BE
died of this cause, nearly 4-fold the number that died o
270 For neonates who
died of those enrolled, consent was requested from paren
271 During follow-up, 1083 study participants
died; of those, 350 individuals died of cardiovascular d
272 One patient
died of thrombosis in the superior mesenteric artery.
273 13 (6%) patients
died of toxicity.
274 Six patients
died of transplant complications following a second HSCT
275 One of 24 patients
died of transplantation-related complications.
276 Among the transplanted patients, 4 children
died of transplantation-related mortality, and 2 additio
277 y higher number of particles than those that
died of trauma and other drivers of mortality.
278 ree patients in the etirinotecan pegol group
died of treatment-related adverse events (pneumonia, mye
279 atients (4%) discontinued treatment, and one
died of treatment-related adverse events.
280 %, 0-2.6) given two delayed intensifications
died of treatment-related causes compared with none in t
281 onset PTLD with the majority of patients who
died of treatment-related causes rather than disease pro
282 No patients
died of treatment-related complications.
283 One patient
died of treatment-related cranial nerve neuropathy.
284 Four patients
died of treatment-related toxicity (arm A, n = 1; arm B,
285 About 1.3 million people
died of tuberculosis in 2012, despite availability of ef
286 Seventeen (77.2%) patients
died of tumor recurrence, and the remaining 5 patients d
287 ied within 5 years of surgery, and 235 (39%)
died of tumor recurrence.
288 Otto
died of typhus two years after his younger brother's dea
289 Danish family members, including a child who
died of unknown causes at 14 months of age.
290 therapy discontinuation and another patient
died of unrelated causes 57 months after therapy complet
291 Ten patients
died of unrelated illnesses within 1 year after transpla
292 92 receiving treatment excluding doxorubicin
died of varicella, metabolic seizure, and sepsis during
293 ears), 4630 were admitted to hospital for or
died of venous thromboembolism.
294 which time 6438 were admitted to hospital or
died of VTE.
295 ,480 men in the cohort, a total of 4,952 men
died, of which 1,637 men died from cardiovascular diseas
296 During follow-up, 81 (12%) patients
died, of which 38 (47%) died from cardiovascular causes.
297 hospitalization, 25% (12/48) of patients had
died, of whom only 1 initiated CAS; 67% (8/12) of these
298 e vs after the mandate, while the percentage
died of wounds (4.1% [83 of 2025] vs 4.3% [380 of 8791];
299 [84 of 278]; P < .01), while the percentage
died of wounds was lower among those critically injured
300 neteen of 67 586 (8%) survivors or those who
died of wounds were recorded to have sustained eye injur